Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

Human clinical trial of investigational calcification inhibitor generates promising results

Cardiovascular calcification is a major health concern in patients with kidney failure undergoing hemodialysis.

3 Oct 2018

Study highlights need for population-specific precision medicine programs in Latin America

Drug safety and effectiveness vary greatly among populations worldwide. Genetics is one of the factors that contribute to variability in drug response.

3 Oct 2018

Eisai's antiepileptic drug receives FDA approval to treat partial-onset seizures in pediatric patients

Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. received approval from the U.S. Food and Drug Administration for an indication expansion for Eisai's antiepileptic drug Fycompa (perampanel) to cover partial-onset seizures in pediatric patients with epilepsy 4 years of age and older.

1 Oct 2018

Cidara initiates Phase 3 clinical trial to evaluate efficacy, safety of rezafungin to treat invasive candidiasis

Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.

27 Sep 2018

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

Decibel Therapeutics and Oricula Therapeutics today announced that Decibel has obtained an exclusive, worldwide license to the development and commercialization of ORC-13661, an oral medication developed by Oricula Therapeutics for the prevention of hearing loss and balance disorders that can occur following treatment of severe infections with aminoglycoside antibiotics.

27 Sep 2018

Biogen and Eisai announce results of LTE Phase 1b study of aducanumab for treating MCI

Biogen and Eisai Co., Ltd. announced results from a recent analysis of the ongoing long-term extension Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment due to Alzheimer's disease and mild AD dementia.

24 Sep 2018

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.

24 Sep 2018

Alector announces initiation of Phase 1 trial of AL001 for treating frontotemporal dementia

Alector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the initiation of its Phase 1 trial called INFRONT, which is evaluating AL001, the company's product candidate for the treatment of a genetically-defined sub-population of patients with frontotemporal dementia.

19 Sep 2018

FDA approves new treatment for people with hairy cell leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

BioIVT announces research into mechanisms involved in cholestatic drug-induced liver injury

BioIVT, a leading provider of research models and services for drug development, today announced its research into the mechanisms involved in cholestatic drug-induced liver injury has been published in Applied In Vitro Toxicology.

10 Sep 2018

Arrowhead completes dosing of ARO-AAT Phase 1 study to treat rare genetic liver disease

Arrowhead Pharmaceuticals Inc. today announced that it has completed dosing of a Phase 1 clinical study of ARO-AAT, the company's second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.

31 Aug 2018

New strategy accelerates, automates process of prototype molecule optimization

The search for new medicinal molecules with predetermined properties is a rather complex, expensive and time-consuming process, especially in oncology.

14 Aug 2018

FDA approves first vaginal ring contraceptive that can be used for one year

The U.S. Food and Drug Administration today approved Annovera (segesterone acetate and ethinyl estradiol vaginal system), which is a combined hormonal contraceptive for women of reproductive age used to prevent pregnancy and is the first vaginal ring contraceptive that can be used for an entire year.

10 Aug 2018

URI researchers working to develop novel medication to treat alcohol use disorder

Alcohol abuse is among the leading causes of preventable death in the United States, killing more than 88,000 people a year, according to the Centers for Disease Control.

28 Jun 2018

Study shows benefits, safety of long-lasting radionuclide therapy for patients with advanced NETs

A first-in-human study presented at the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging demonstrates the benefits and safety of a new, long-lasting type of radionuclide therapy for patients with advanced, metastatic neuroendocrine tumors.

26 Jun 2018

AAA doses first patients in two clinical studies with PSMA-R2 for prostate cancer

Advanced Accelerator Applications S.A., a Novartis company and leader in nuclear medicine theragnostics, today announced that the first patients have been dosed in two Phase I/II clinical studies of radiolabeled PSMA-R2, a urea-based ligand of Prostate-Specific Membrane Antigen, which is commonly expressed on prostate cancer cells.

22 Jun 2018

Scientists introduce combination approach to fight cancer

For efficient cancer therapy with few side effects, the active drug should selectively attain high concentration in the tumor. In the journal Angewandte Chemie, scientists have introduced a new approach, in which two synergistic drug components are combined into a dimer.

31 May 2018

Scientists develop a new approach for efficient cancer therapy

For efficient cancer therapy with few side effects, the active drug should selectively attain high concentration in the tumor.

30 May 2018

Alexo Therapeutics marks next significant milestone by initiating ALX148 combination cohorts

Alexo Therapeutics, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced it has initiated ALX148 combination dosing with targeted antibody therapies in its Phase 1 clinical program in patients with advanced solid tumors and lymphoma.

17 May 2018

Aravive Biologics demonstrates proof-of-mechanism for AVB-S6-500 in ongoing phase 1 study

Aravive Biologics, Inc. announced today that the company has demonstrated clinical proof-of-mechanism for AVB-S6-500 in neutralizing GAS6, based on analysis of the single ascending dose portion of the ongoing Phase 1 study.

10 May 2018